Skip to main content
Clinical Trials/NCT05268822
NCT05268822
Completed
Not Applicable

Movement Control Exercises With and Without Specific Breathing Techniques for the Treatment of Chronic Low Back Pain: an Open-label Feasibility Study With 2-month

Kuopio University Hospital1 site in 1 country30 target enrollmentFebruary 8, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Low-back Pain
Sponsor
Kuopio University Hospital
Enrollment
30
Locations
1
Primary Endpoint
Well-Being in Pain Questionnaire
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Chronic low back pain (CLBP) is a leading disability globally. Exercise therapies are one of the most commonly prescribed treatment options for CLBP. Specific breathing techniques have been shown to enhance brain-based pain modulation and autonomic nervous system balance; these changes have been shown to improve clinical effectiveness in terms of pain management and psychological factors compared to general exercise. However, no previous studies have added a specific breathing technique protocol to an evidence-based exercise program for CLBP.

Registry
clinicaltrials.gov
Start Date
February 8, 2022
End Date
November 14, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Kuopio University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Jani Mikkonen

Principal Investigator / PhD student at Institute of Clinical Medicine

Kuopio University Hospital

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18-68-years-old
  • Low back pain lasting more than 3 months (pain sensation more than 3 days per week)
  • A numerical pain scale of more than 3
  • ≥ 2/6 positive low back movement control tests (as described by Luomajoki et al.)
  • Roland-Morris Disability Questionnaire score of five or greater
  • Who are physically able to perform movement control tests and provide written informed consent.

Exclusion Criteria

  • Any history of malignant cancer
  • Neurological disease affecting the central nervous system (MS, dementia)
  • Rheumatic disease (fibromyalgia, ankylosing spondylitis/rheumatoid arthritis)
  • Chronic obstructive pulmonary disease,
  • Spinal surgery in the last 12 months
  • A cardiac pacemaker
  • Signs and symptoms of nerve root pathology during the clinic visits.
  • Women who become pregnant during the data collection will also be excluded from the study.

Outcomes

Primary Outcomes

Well-Being in Pain Questionnaire

Time Frame: Change from Baseline Well-Being in Pain Questionnaire at 2 months

Self-developed questionnaire to screen the effects of pain on a person's biopsychosocial well-being. Scale from 0 (no subjective well-being in pain) to 60 (maximum subjective well-being in pain)

The numerical pain rating scale (NRPS)

Time Frame: Change from Baseline The numerical pain rating scale at 2 months

Eleven-point numerical pain scale. Scale from 0 (no pain) to 10 (worst imaginable)

The Tampa Scale of Kinesiophobia (TSK)

Time Frame: Change from Baseline The Tampa scale of Kinesiophobia at two months

Assessment of subjective kinesiophobia (fear of movement). Scale from 17 (the minimal kinesophobia) to 68 (the most maximum kinesiophobia).

The Roland Morris Disability Questionnaire (RMDQ)

Time Frame: Change from Baseline The Roland Morris Disability Questionnaire at 2 months

Questionnaire measuring disability in chronic low back pain populations. Scale from 0 (no disability) to 24 (maximum low back pain related disability)

The Pain and Sleep Questionnaire Three-Item Index (PSQ-3)

Time Frame: Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months

Effect of pain on sleep. Scale from 0 (pain have no any effect on sleep) to 30 (pain have maximum effect on sleep)

The Pain Catastrophizing Scale (PCS)

Time Frame: Change from Baseline he Pain Catastrophizing Scale at two months

Assessment of catastrophizing (tendency to magnify the threat value of a pain stimulus) related to pain. Scale from 0 (no catastrophizing thoughts) to 52 (maximum catastrophizing thoughts)

Central Sensitization Inventory (CSI)

Time Frame: Change from Baseline Central Sensitization Inventory at two months

Screening of central sensitization phenomenon. Scale from 0 (no central sensitization) to 100 (worst imaginable central sensitization)

The 5-level EQ-5D version of the EuroQol

Time Frame: Change from Baseline The 5-level EQ-5D version of the EuroQol at 2 months

Health status. Scale from 0 (dead) to 1 (full health)

The Generalised Anxiety Disorder Assessment (GAD-7)

Time Frame: Change from Baseline The Generalised Anxiety Disorder Assessment at two months

Measure of generalised anxiety disorder related symptoms. Scale from 0 (the most minimal anxiety) to 21 (the most severe anxiety)

The Pain Self-Efficacy Questionnaire (PSEQ)

Time Frame: Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months

assess the self-efficacy of people in pain have in daily activities. The scale is from 0 points (not at all confident) to 6 points (completely confident).

Secondary Outcomes

  • Quantifying(Through study completion, an average of 2 months)
  • Feasibility of intervention protocol, recruitment and enrollment(Through study completion, an average of 2 mothns)
  • Responsiveness(Through study completion, an average of 2 months)

Study Sites (1)

Loading locations...

Similar Trials